Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data

Current Medical Research and Opinion

Volumn 23, Issue 8, 2007, Pages 1749-1759

  Wu, Eric Qiong ^a   Chen, Lei ^a   Birnbaum, Howard ^a   Yang, Elaine ^a   Cifaldi, Mary ^b  

^a ANALYSIS GROUP   (United States)

^b ABBOTT LABORATORIES   (United States)

Author keywords

Adalimumab; Claims data; Cost; Etanercept; Infliximab; Rheumatoid arthritis; TNF antagonist

Indexed keywords

ADALIMUMAB; ANALGESIC AGENT; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB;

ADULT; AGED; ARTICLE; BILLING AND CLAIMS; COMORBIDITY; CONTROLLED STUDY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FEMALE; HEALTH SERVICES; HUMANS; IMMUNOGLOBULIN G; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34548133089     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X210615     Document Type: Article

References (18)

1. Rosery H, Bergemann R, Maxion-Bergemann S. International variation in resource utilisation and treatment costs for rheumatoid arthritis: a systematic literature review. Pharmacoeconomics 2005;23:243-57
2. Ward MM, Javitz HS, Yelin EH. The direct cost of rheumatoid arthritis. Value Health 2000;3:243-52
3. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. National Arthritis Data Work Groups. Arthritis Rheum 1995;38:1351-62
4. Birnbaum HG, Barton M, Greenberg PE, et al. Direct and indirect costs of rheumatoid arthritis to an employer. J Occup Environ Med 2000;42:588-96
5. Yelin E. The costs of rheumatoid arthritis: absolute, incremental, and marginal estimates. J Rheumatol Suppl 1996;44:47-51
6. Weaver AL. The impact of new biologicals in the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2004;43(Suppl 3):iii, 17-23
7. Haraoui B. The anti-tumor necrosis factor agents are a major advance in the treatment of rheumatoid arthritis. J Rheumatol Suppl 2005;72:46-7
8. Lyseng-Williamson KA, Plosker GL. Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:1071-95
9. Lyseng-Williamson KA, Foster RH. Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics 2004;22:107-32
10. Bansback NJ, Brennan A, Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005;64:995-1002
11. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm 2006;12:555-69
12. Gilbert TD Jr, Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. BMC Musculoskelet Disord 2004;5:36
13. Ollendorf DA, Massarotti E, Birbara C, Burgess SM. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. J Manag Care Pharm 2005;11:383-93
14. Weycker D, Yu EB, Woolley JM, Oster G. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or = 65 years with rheumatoid arthritis. Clin Ther 2005;27:646-56
15. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
16. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19
17. Imbens GW. The role of the propensity score in estimating dose-response functions. Biometrika 2000;87:706-10
18. D'Agostino RB. Tutorial in biostatistics: propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Statist Med 1998:17:2265-81